Access

Letters to Editor

Nature Medicine 6, 1194 (2000)
doi:10.1038/81251

The Quest Trial, a paradigm of HIV collaborative research

Li-Ean Goh1, Hugh McDade1, Sabine Kinloch2, Luc Perrin3, David Cooper4, Andrew Phillips5, Bruno Hoen6, Brigitte Autran7, Anders Sonnerborg8 & Chris Tsoukas9

  1. GlaxoWellcome HIV Clinical Research, London, UK e-mail: lg6017@glaxowellcome.co.uk
  2. Royal Free Hospital, London, UK
  3. University of Geneva, Geneva, Switzerland
  4. National Centre in HIV, Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
  5. Royal Free & University College Medical School, London, UK
  6. University Medical Centre, Besancon, France
  7. Laboratoire d'immunologie Cellulaire et Tissulaire, Hopital Pitie Salpetriere, Paris, France
  8. Karolinska Institutet, Stockholm, Sweden
  9. Montreal General Hospital, Montreal, Canada

A recent News story in your journal addressed the issue of whether there is a commitment to move forward with the development of preventive vaccines for principal infectious diseases, including human immunodeficiency virus (HIV)-1 infection, tuberculosis and malaria1. For HIV-1, although it is accepted that prophylactic vaccines are an urgent priority to prevent new infections, the plight of those already infected must also be considered.